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The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added
every 3 weeks to the standard combination dose of capecitabine. Cohorts of at least three patients with pretreated gastrointestinal
carcinoma received capecitabine 1000mg m
 2 orally twice daily on days 1–14 plus i.v. bolus mitomycin C on day 1 at doses of 4, 6, 8
or 10mg m
 2 (corresponding to dose levels I–IV). Cycles were repeated every 3 weeks. Two treatment cycles were considered for
the evaluation of DLTs. Of the 53 patients enrolled, the majority had colorectal (n¼27) or gastric (n¼14) cancers. Patients had
received a median of two lines of prior chemotherapy (34% with X3 lines and 87% with prior 5-FU-based therapy). At the
recommended dose level (IV, n¼30), grade 3 adverse events during cycles 1 and 2 were: anaemia (10%); leukopenia (3%);
thrombocytopenia (3%); stomatitis/mucositis (3%); hand–foot syndrome (3%). Two patients experienced DLTs (mucositis, n¼1;
neutropenic fever, n¼1), but there were no grade 4 events. The median dose intensity for capecitabine and mitomycin C was 100%
during cycles 1 and 2 and only four patients required postponement of therapy. Of the 43 patients evaluable for efficacy, seven
achieved partial and minor remissions (16%; 95% CI, 5–28%), and 12 patients (28%) had stable disease. The favourable safety profile
and promising activity of the capecitabine/mitomycin C combination, even in heavily pretreated patients, warrant further evaluation in
patients with advanced colorectal and gastric cancers.
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Front-line chemotherapy for patients with advanced/metastatic
cancer of the digestive tract is frequently based on 5-fluorouracil
(5-FU)7folinic acid (FA). Capecitabine is an oral fluoropyrimi-
dine carbamate designed to mimic the pharmacokinetics of
infusional 5-FU and produce high concentrations of 5-FU
preferentially in tumour tissue. Capecitabine is converted to its
active metabolite 5-FU through a three-step enzymatic process, the
final step of which is mediated by the enzyme thymidine
phosphorylase (Schu ¨ller et al, 2000). As first-line treatment for
metastatic colorectal cancer, capecitabine produces a higher
response rate than bolus 5-FU/FA and is at least equivalent in
terms of time to disease progression (TTP) and overall survival
(Twelves (2002)). In addition, capecitabine causes less diarrhoea,
stomatitis, nausea, alopecia and neutropenia (Cassidy et al, 2002).
Capecitabine has also demonstrated promising activity in other
gastrointestinal cancers, as either a single agent or in combination
with oxaliplatin (Borner et al, 2002), irinotecan (Tewes et al, 2003)
or gemcitabine (Scheithauer et al, 2003).
Mitomycin C is one of the most effective single agents
for gastrointestinal cancer. In addition, there is evidence for in
vitro synergy between mitomycin and bolus 5-FU (Sartorelli
and Boothe, 1965), although the cellular mechanism of the
clinically observed synergy between mitomycin and infusional
5-FU has not been further elucidated. Nevertheless, time-
dependent interactions between both drugs have been reported
in human cancer cell lines (Rusello et al, 1989). Combination
treatment with mitomycin C and bolus 5-FU/FA is both active
and well tolerated in patients with advanced gastric cancer
(Hartung et al, 2000). The addition of mitomycin to infusional
5-FU is also effective and well tolerated as first- or second-line
therapy in patients with gastrointestinal tumours (Hartmann
et al, 2003. Hofheinz et al, 2004). Mitomycin (10mg m
 2)
added every third week to weekly infusional high-dose 5-FU/FA
yielded a response rate of 54%, and an overall survival of
10.2 months in patients with advanced gastric cancer (Hofheinz
et al, 2002). In a randomised study comparing ECF (three-weekly
epirubicin and cisplatin with protracted venous infusional (PVI)
5-FU 200mg m
 2 daily) to MCF (mitomycin 7mg m
 2 every
6 weeks and three-weekly cisplatin with PVI-5-FU 300mg m
 2
daily) in patients with advanced oesophagogastric cancer,
both regimens resulted in equivalent response rates and
survival (Ross et al, 2002), thus confirming the efficacy of
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lcombined infusional 5-FU and mitomycin C. In patients with
either colorectal or pancreatic cancer, PVI-5-FU plus MMC
resulted in a superior response rate (and an improved TTP in
colorectal cancer) compared with PVI-5-FU alone (Ross et al, 1997.
Maisey et al, 2002).
As in the colorectal cancer setting, capecitabine is now replacing
infusional 5-FU in combination with other agents such as
mitomycin C due to its similar pharmacokinetic properties and
superior tolerability and convenience. Furthermore, the antitumour
activity of capecitabine is likely to be enhanced by the upregulation
of thymidine phosphorylase activity by mitomycin C (Yamshita
et al, 2001). Among various cytostatics studied in combination with
capecitabine in human cancer xenografts, mitomycin C and the
taxanes have the highest potential of increasing the levels of
intratumoral thymidine phosphorylase (Sawada et al, 1998). The
clinical relevance of upregulating thymidine phosphorylase has
already been demonstrated for capecitabine in combination with
docetaxel (7epirubicin) in patients with advanced breast cancer
(O’Shaughnessy et al, 2002; Venturini et al, 2002).
The present phase I study was designed to evaluate the
recommended dose and dose-limiting toxicities (DLTs) of
capecitabine in combination with mitomycin C in patients with
previously treated advanced gastrointestinal cancers.
PATIENTS AND METHODS
The study protocol was reviewed and approved by the local
institutional review boards of the participating institutions and the
study was performed according to the Declaration of Helsinki. All
patients provided written informed consent prior to entry into the
study.
Eligibility criteria
Patients with histologically confirmed gastrointestinal cancer
refractory to or relapsed after at least one chemotherapy regimen
for metastatic disease were eligible for entry into the study.
Previous anticancer therapy was not permitted within the 4-week
period immediately prior to study commencement. Other elig-
ibility criteria included an Eastern Cooperative Oncology Group
(ECOG) performance status p2, age X18 years, a life expectancy
of X3 months, and adequate bone marrow function (leucocyte
count 43000ml
 1, platelet count 4100000ml
 1). Patients were
also required to have adequate renal (serum creatinine
p1.4mgdl
 1 or creatinine clearance 460mlmin
 1) and hepatic
function (bilirubin p2mgdl
 1). Left ventricular ejection fraction
(LVEF) had to be X50%. Patients of childbearing potential were
required to be using appropriate contraception.
Staging procedures
Before study admission, all patients underwent a complete history,
physical examination, ECG and chest X-rays. Cardiac ultrasono-
graphy was carried out to determine the LVEF. A full blood count
with differential and serum chemistry was obtained within 14 days
prior to the start of treatment. Weekly blood counts were obtained
and serum chemistry repeated every 3rd week or whenever
clinically indicated. Assessment of LVEF was repeated before the
initiation of every other treatment cycle. Computed tomography
(CT) scans of the tumour-bearing region were recommended and
performed within 4 weeks prior to the start of study treatment.
Indicator lesions were assessed every 6 weeks.
Treatment schedule and dose escalation
Capecitabine was administered orally within 30min after a meal
(generally after breakfast and evening meal) at a dose of
1000mgm
 2 twice daily on days 1–14, every 3 weeks. Mitomycin
C was administered by i.v. bolus on day 1 of each cycle at escalating
doses (4, 6, 8 or 10mgm
 2, corresponding to dose levels I–IV).
Dexamethasone 8mg was added intravenously to mitomycin C to
prevent pulmonary toxicity. All patients received standard antiemetic
prophylaxis to avoid any bias relating to gastrointestinal toxicities.
Dose-limiting toxicities during the first two cycles of che-
motherapy were defined by the occurrence of one of the following
toxicities: grade 4 leucopenia/neutropenia or thrombocytopenia,
symptomatic thrombocytopenia (haemorrhage), grade 3 or 4
febrile neutropenia or any Xgrade 3 nonhaematological toxicity
except nausea/vomiting. At least three patients were enrolled per
dose level, with this number being increased to six if DLTs
occurred in more than one patient. Dose escalation was halted if
DLT occurred in two or more patients. The maximum tolerated
dose (MTD) was defined as the highest dose at which fewer than
two or three of six patients experienced DLTs during the first
course of chemotherapy. Escalation beyond dose level IV was not
foreseen and individual dose escalation was not allowed.
To adequately determine the safety of this combination, the
recruitment of further patients at the MTD or at the highest
investigated dose level (IV) was planned in the study protocol.
Safety and efficacy analyses
Adverse events were recorded weekly and graded according to
National Cancer Institute Common Toxicity Criteria (NCI-CTC,
version 2.0). In terms of efficacy, complete response (CR), partial
response (PR), minor response (MR), stable disease (SD) and
progressive disease (PD) were defined according to WHO criteria.
Survival was defined as the time between the start of chemotherapy
and death, according to the Kaplan–Meier method (Kaplan and
Maier, 1958).
Statistical considerations
The rate of DLTs during the expanded study phase was required to
be lower than 17% (i.e. about one out of six of the patients). With a
total of 32 patients, a rate of at least 83% of the patients
experiencing no DLTs during cycles one and two can be excluded
using Simon’s two-stage design with a power of 80% and an a-
value of 0.2 if less than five out of 15 (first stage) or eight out of 32
patients (second stage) experienced DLTs.
RESULTS
Patient characteristics
A total of 53 patients were enrolled at three institutions between
November 2001 and January 2003. Of these, 49 were evaluable for
safety. The remaining four patients were withdrawn for the
following reasons: lost to follow-up (n¼1); violation of inclusion
criteria (n¼1); therapy discontinuation after 1 week due to ileus in
need of surgery (n¼1); and port infection with septic fever and
need of port revision (n¼1).
Characteristics of enrolled patients are described in Table 1. The
majority of patients (85%) had an ECOG status X1. Colorectal
cancer (51%) and gastric cancer (26%) were the most common
malignancies. The liver and lung were the most common sites of
metastases, followed by lymph nodes and peritoneal carcinoma-
tosis. Patients with colorectal cancer had received a median of
three lines of prior chemotherapy and 87% of patients had received
prior 5-FU-based treatment.
Determination of the MTD and dose intensity
Three patients were enrolled at dose level I, seven at dose level II,
nine at dose level III and 34 at dose level IV. Patients treated at
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ldose levels I–III received a total of 31 cycles of chemotherapy. As
allowed – but not formally requested – by the protocol, the number
of patients treated at dose levels II and III was expanded to seven
and nine, respectively, to have a more thorough estimation of the
safety of the investigational regimen. None of the patients treated
at dose levels I–III developed DLTs (Table 2). Furthermore, none
of the first six patients treated at dose level IV had dose-limiting
side effects, as well, and consequently a total of 34 patients were
recruited at this dose level receiving a total of 124 treatment cycles.
Of these patients, four were not evaluable for the previously
mentioned reasons. Two of these patients formally had serious
adverse events (port infection (n¼1) and ileus due to tumour-
related bowel obstruction (n¼1)) clearly not related to the study
treatment. Of the remaining 30 patients, two developed DLTs:
neutropenic fever (n¼1) and mucositis grade III (n¼1). Thus, as
foreseen by the protocol, a DLT rate of 417% could be excluded
with a power of 80% and an a-value of 0.2.
Dose intensity was calculated for all patients treated at the
recommended dose (level IV). Taking all 30 patients into account,
a median dose intensity of 100% was reached during cycles one
and two for each drug (Figure 1). Postponement of treatment
(which did not exceed 7 days in each case) was required during
cycles one and two in only four patients. In addition, 15 patients
(50%) received a third and fourth cycle of chemotherapy. The
calculated median dose intensities for these patients in cycles three
and four were capecitabine 100% and mitomycin C 89%. Seven of
these 15 patients had a therapy delay during cycles three and four,
with a median delay of 8 days (range 7–28 days). Three patients
continued therapy and received at least five cycles of treatment.
At the recommended dose level, the mean cumulative dose of
mitomycin C was 56mg (median 47mg; range 18–120mg). At this
level, 75% of the 30 patients received more than 36mg of
mitomycin C and 25% received more than 76mg.
Safety
Table 2 summarises haematological and nonhaematological
adverse events during the first and second cycles (the time period
for the determination of DLTs, i.e. days 1–42) and cycles three and
four. No DLTs occurred at dose levels I–III. At dose level IV, a
total of 30 patients were evaluable for safety. Leukopenia (n¼14),
thrombocytopenia (n¼14), nausea/vomiting (n¼14) and diar-
rhoea (n¼8) were the most commonly observed adverse events
during cycles one and two, while grade III events were observed in
only four patients. Among 15 patients treated during cycles three
and four, eight suffered from thrombocytopenia with a tendency
towards higher grades of adverse events (grade 1, n¼3; grade 2,
n¼3; grade 3, n¼2) compared with cycles one and two. Both
patients with grade 3 thrombocytopenia had been pretreated with
cisplatinum for several months. One patient developed thrombo-
cytopenia after a cumulative dose of 20mgm
 2 mitomycin C
starting on day 30 and another patient after 30mgm
 2 (starting on
day 55). However, no episodes of thrombocytopenic bleeding were
reported. Grade 3 stomatitis/mucositis was observed in one patient
Table 1 Patient demographics
Variable No. of patients (%)
Enrolled 53 (100)
Evaluable 49 (92)
Age (years)
Median 61
Range 38–76
Gender
Male 35 (66)
Female 18 (34)
Performance status (ECOG)
Median 1
0 8 (15)
1 32 (60)
2 13 (25)
Primary tumour site
Colorectal cancer 27 (51)
Gastric cancer 14 (26)
Pancreatic cancer 5 (9)
Oesophageal cancer 4 (8)
Others 3 (6)
Prior chemotherapy
0–1 line 18 (34)
2 lines 17 (32)
X3 lines 18 (34)
5-FU based (i.v. or oral) 46 (87)
Tumour localisation
Primary 14 (26)
Liver 35 (66)
Lung 24 (45)
Lymph nodes 16 (30)
Peritoneal carcinomatosis 14 (26)
Table 2 Haematological and nonhaematological adverse events per dose level in cycles one and two and in subsequent cycles (worst per patient)
No. of patients/NCI-CTC grade
Dose
level
Patients
(n) Anaemia Leucocytopenia Thrombocytopenia Nausea/vomiting Stomatitis/mucositis Diarrhoea Creatinine HFS
1 2 3 4 1234 1 2 3 4 1 / 2 3 4 1 / 2 3 4 1 / 2 3 41 2 1 2 3
Cycles 1/2
I 3 – – – – –––– – – – – 3 – – – – – 1– –– –1 – –
I I 7 3 1 – – 1––– 3 – – – 2 – – – – – 1– – 2 –2 1 –
I I I 9 – 2 – – –––– 2 – – – 4 – – 3 – – 3– –– – – 1 –
IV 30 8 8 3 – 7 6 1 – 10 3 1 – 14 – – 2 1 – 8 – – 2 1 3 – 1
Cycles 3/4
I 2 – – – – –––– – – – – – – – 1 – – 1– –– –1 1 –
I I 4 – 2 1– 1 – 1 – 2 – 1 – – – – – – – 1 – – – – –––
I I I 4 – – – – –––– 1 – – – 3 – – – – – 1– –– – – – –
IV 15 4 3 – – 2 1 1 – 3 3 2 – 1 1 – 1 – – 1 – – – 1 1 2 –
Creat¼creatinine; HFS¼hand–foot syndrome.
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land hand–foot syndrome (HFS) was seen in four patients at dose
level IV during cycles one and two, although only one patient
developed grade 3 HFS. No prophylactic measures against HFS
(e.g. vitamin B6) were in place.
Slight elevations of serum creatinine were seen in five out of 49
(10%) patients evaluable for safety (grade 1, n¼4; grade 2, n¼1).
No evidence of mitomycin C-induced haemolytic–uraemic syn-
drome was documented.
Antitumour activity
Of the 27 patients with metastatic colorectal cancer enrolled, 25
were evaluable for antitumour response. These patients had
received a median of three lines of prior chemotherapy, including
5-FU and either irinotecan or oxaliplatin or both. In two patients,
tumour remissions were observed (8%; 95% confidence interval
(CI) 0–19%). One patient each was refractory to two or three prior
regimens, respectively. Seven patients (28%, five of whom were
refractory) had SD following treatment. The median progression-
free survival for all patients with colorectal cancer was 2.0 months,
for patients with clinical benefit (PR and NC) 3.0 months (range
2.0–47.6 months).
Of the 14 patients who had metastatic gastric cancer, 11 were
evaluable for antitumour activity. Tumour shrinkage was noted in
two of these patients (18%; 95% CI 0–45%), fulfilling the criteria
for PR in one relapsed patient. Four patients (36%) had SD with a
mean time of SD of 2.8 months (range 2.2–3.7 months). The
median progression-free survival for all patients with gastric
cancer was 2.3 months, for patients with clinical benefit 3.0 months
(range 1.4–4.2 months). Furthermore, two patients with refractory
pancreatic cancer had SD (lasting 3.4 and 3.2 months, respectively)
and two patients with squamous cell carcinoma of the oesophagus
had remissions lasting for 3.8 and 45.8 months.
DISCUSSION
Our current findings indicate that mitomycin C at a dose of 10mg
m
 2 on day 1 in combination with capecitabine 1000mgm
 2 twice
daily on days 1–14 every 3 weeks is both effective and well
tolerated, with an adverse event profile similar to capecitabine
monotherapy (Cassidy et al, 2002). Dose escalation in this phase I
study continued to the highest dose level (IV) without the
occurrence of DLTs at lower dose levels. At dose level IV, only
two patients experienced a DLT. Gastrointestinal adverse events
were infrequent, although haematological adverse events, pre-
dominantly thrombocytopenia, were more pronounced.
A total of 15 patients received at least four cycles of
chemotherapy. During cycles three and four, higher grades of
thrombocytopenia were noted. This shift in toxicity was expected
because delayed thrombocytopenia is known to develop after
prolonged therapy with mitomycin C. Mainly because of this
adverse event, an observation period of 6 weeks (two courses of
chemotherapy) for the development of DLTs was required by the
protocol. Nevertheless, dose intensity for mitomycin C was
maintained at 100% during the first two cycles (n¼30 patients),
and 89% during cycles three and four (n¼15 patients). In
addition, there were no episodes of haemolytic uraemic syndrome
or pulmonary toxicities during the study.
Our safety data are comparable to findings from two studies
published as abstracts by Rao et al (2003) and Watkins et al (2003)
from the Royal Marsden Hospital, UK. The authors reported on
patients with metastatic colorectal cancer (first line, n¼55; third
line, n¼31), who received capecitabine 1250mgm
 2 twice daily
for 14 days, every 3 weeks, in combination with mitomycin C as a
bolus of 7mgm
 2 on day 1, every 6 weeks. The proportion of
patients experiencing grade 3/4 adverse events with this low-dose
mitomycin C/high-dose capecitabine regimen were as follows (first
line vs third line): thrombocytopenia (3.6% vs not reported);
neutropenia (3.7 vs 1.8%); anaemia (0 vs 7.4%); diarrhoea (14.3 vs
3.9%); nausea/vomiting (1.8 vs 11.5%). In addition, the safety
profile of the same schedule evaluated in 27 patients with
colorectal cancer treated on a compassionate use basis after failure
of 5-FU, irinotecan and oxaliplatin (Harba et al, 2003) was
reported to be in the same range as in the Royal Marsden studies
and in our phase I study.
The patients in our study were heavily pretreated with a median
of three regimens of prior chemotherapy for colorectal cancer and
one regimen for gastric cancer. Nevertheless, we observed tumour
regressions in patients with either tumour type. The response rate
of 8% and SD rate of 28% observed in the 25 patients with
colorectal cancer is almost identical to that reported by Harba et al
(response rate 10%, SD 30%), but somewhat lower than that from
the Royal Marsden study (response rate 22%, SD 57%) (Rao et al,
2003), both of which studied the combination in the salvage
setting. Nevertheless, the patients included in the latter study had
not received prior oxaliplatin. Of note are the results from the
Royal Marsden study examining capecitabine/mitomycin C as
first-line chemotherapy, including an overall response rate of 40%
(95% CI, 26.4–54.0%), a median survival of nearly 15 months and
a median TTP of 7.2 months (Watkins et al, 2003). These findings
with capecitabine/mitomycin C as front-line therapy in metastatic
colorectal cancer compare well with 5-FU/irinotecan or 5-FU/
oxaliplatin combination studies (de Gramont et al, 2000; Douillard
et al, 2000; Saltz et al, 2000). Examining the results from all four
trials on capecitabine/mitomycin C therapy reveals that a response
rate of approximately 40% can be achieved in chemonaı ¨ve patients,
while every round of pretreatment appears to reduce the likelihood
of response by an estimated 10% (response rate of 10% after 5-FU/
irinotecan/oxaliplatin (Harba et al, 2003. present study), response
rate of 20% after 5-FU/irinotecan (Rao et al (2003)), response rate
of 30% after 5-FU monotherapy).
Meanwhile, data on patients with advanced biliary tract cancer
have been published that indicate that the mitomycin C and
capecitabine combination regimen (mitomycin C 8mgm
 2 on day
1 plus capecitabin 1000mgm
 2 twice daily on days 1–14, every 4
weeks) may also be a promising therapeutic option for this type of
cancer (Kornek et al, 2004).
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Figure 1 Dose intensity (%) in patients treated at the recommended dose during cycles one/two (n¼30), and three/four (n¼15).
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lIn conclusion, we have established a dosing schedule for the
combination of capecitabine and mitomycin C that is both well
tolerated and effective for the treatment of patients with previously
treated advanced/metastatic colorectal and gastric cancer. Activity
was also seen in pancreatic cancer and squamous cell carcinoma of
the oesophagus. This regimen may be considered for patients with
colorectal cancer after pretreatment with 5-FU, irinotecan and
oxaliplatin, but it is also likely to be a valuable, cost-saving and
convenient treatment option even in earlier stages of colorectal
cancer chemotherapy. Our results in gastric cancer patients,
together with our earlier reported experience with infusional 5-FU/
mitomycin C combination therapy in this type of cancer
(Hartmann et al, 2003; Hofheinz et al, 2002), suggest that the
capecitabine/mitomycin C regimen could be considered as an
alternative regimen for patients not suitable for cisplatin-based
therapy.
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